このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Deciphera Pharmaceuticals マネジメント
マネジメント 基準チェック /34
Deciphera Pharmaceuticals'の CEO はSteve Hoerterで、 Mar2019年に任命され、 の在任期間は 5.25年です。 の年間総報酬は$ 6.01Mで、 12.3%給与と87.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.084%を直接所有しており、その価値は$ 1.86M 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と9年です。
主要情報
Steve Hoerter
最高経営責任者
US$6.0m
報酬総額
| CEO給与比率 | 12.3% |
| CEO在任期間 | 5.3yrs |
| CEOの所有権 | 0.08% |
| 経営陣の平均在職期間 | 4.3yrs |
| 取締役会の平均在任期間 | 9yrs |
経営陣の近況
Recent updates
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up
Apr 30
Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$190m |
| Dec 31 2023 | US$6m | US$738k | -US$195m |
| Sep 30 2023 | n/a | n/a | -US$194m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$182m |
| Dec 31 2022 | US$4m | US$703k | -US$179m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$258m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$9m | US$676k | -US$300m |
| Sep 30 2021 | n/a | n/a | -US$274m |
| Jun 30 2021 | n/a | n/a | -US$258m |
| Mar 31 2021 | n/a | n/a | -US$255m |
| Dec 31 2020 | US$8m | US$650k | -US$266m |
| Sep 30 2020 | n/a | n/a | -US$271m |
| Jun 30 2020 | n/a | n/a | -US$263m |
| Mar 31 2020 | n/a | n/a | -US$218m |
| Dec 31 2019 | US$9m | US$435k | -US$192m |
| Sep 30 2019 | n/a | n/a | -US$157m |
| Jun 30 2019 | n/a | n/a | -US$126m |
| Mar 31 2019 | n/a | n/a | -US$126m |
| Dec 31 2018 | US$447k | n/a | -US$100m |
報酬と市場: Steveの 総報酬 ($USD 6.01M ) は、 US市場 ($USD 5.67M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Steveの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Steve Hoerter (53 yo)
5.3yrs
在職期間
US$6,010,712
報酬
Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 5.3yrs | US$6.01m | 0.084% $ 1.9m | |
| Executive VP | 9.3yrs | US$2.03m | 0.049% $ 1.1m | |
| Executive VP & Chief Scientific Officer | less than a year | US$3.06m | 0% $ 0 | |
| Senior VP & Chief Commercial Officer | 5.8yrs | US$1.58m | 0.036% $ 801.7k | |
| Executive VP & Chief Medical Officer | 4.7yrs | US$2.13m | 0.084% $ 1.8m | |
| Senior VP & Chief Technical Officer | less than a year | データなし | データなし | |
| Senior Vice President of Finance & Investor Relations | no data | データなし | データなし | |
| Senior VP & General Counsel | 5.3yrs | データなし | データなし | |
| Senior VP & Chief Human Resources Officer | 2.4yrs | データなし | データなし | |
| Senior VP & Chief Development Officer | 4.3yrs | データなし | 0.040% $ 876.3k | |
| Senior VP & Head of International | 3.3yrs | データなし | データなし | |
| Senior Vice President of Clinical Development | 3.4yrs | データなし | データなし |
4.3yrs
平均在職期間
53yo
平均年齢
経験豊富な経営陣: DCPHの経営陣は 経験豊富 であると考えられます ( 4.3年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.1yrs | US$6.01m | 0.084% $ 1.9m | |
| Independent Director | 9.3yrs | US$388.59k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$396.09k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$398.55k | 0% $ 0 | |
| Independent Chairman | 4.5yrs | US$403.30k | 0% $ 0 | |
| Member of Scientific Advisory Board | 9yrs | データなし | データなし | |
| Independent Director | 16.8yrs | US$414.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | 9yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 9yrs | データなし | データなし | |
| Independent Director | 9.3yrs | US$386.05k | 0.013% $ 281.5k | |
| Member of Scientific Advisory Board | no data | データなし | データなし |
9.0yrs
平均在職期間
62yo
平均年齢
経験豊富なボード: DCPHの 取締役会 は 経験豊富 であると考えられます ( 9年の平均在任期間)。